Compare Novartis AG (NVS) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Novartis AG trades at $152.35 (market cap $295.37B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.17. The key difference: Novartis AG pays a 3.07% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none, and Novartis AG is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| NVS | QCLN | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $68.47 |
52-Week Low | $119.31 | $36.11 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
QCLN trades at $53.17, up 2.15% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights clean energy ETF growth driven by data center demand and geopolitical shifts, though regulatory hurdles and supply chain costs pose challenges. The stock lacks disclosed financial ratios, requiring deeper fundamental review.
Outlook is cautiously optimistic given sector tailwinds, but investment hinges on policy stability and cost management. Risks include U.S. permit delays and Chinese trade tensions, while institutional sentiment appears mixed amid volatile clean energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
